Here are four notes:
1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.”
2. The letter says of the nearly 69,000 biomedical researchers working in the United States, almost 50 percent are born outside the nation’s borders.
3. Many of the executives’ colleagues feel the order gives the message that America is not accepting of any immigrants, even if the ban currently only applies to seven countries. The letter states, “Several among us have heard from employees about their deportation fears, how they do not feel comfortable leaving the country on business or how they now feel cut off from their family abroad.”
4. The executive ban could have a major fallout in the biotechnology industry, the letter argues. The authors also state the industry is one that will play a crucial role moving forward in the 21st century.
More articles on healthcare:
Building an ASC management & development roadmap for the future
Motus GI raises $25.6M in new fundraising round: 4 key notes
Survey: Virtual services in high consumer demand: 5 key notes
